The inhibition of methionine adenosyltransferase 2A (MAT2A) in cancers harboring deletions of the methylthioadenosine phosphorylase (MTAP) gene induces synthetic lethality, making it a highly compelling strategy in the pursuit of precision anticancer therapeutics. The gene discussed is MAT2A; the disease is cancer.